Background Targeting CTLA-4 is a recent strategic approach in cancer control: blocking
CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T …

Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

Anti-drug antibodies (ADAbs) develop in up to a third of patients treated with biologic agents,
with such immunogenicity being one of the main reasons for the loss of efficacy observed in …

Objectives To evaluate the prevalence and type of rheumatic immune-related adverse
events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the …

Objective Immune checkpoint inhibitors (ICI s) for cancer therapy frequently induce immune‐
related adverse effects (IRAE s). Therefore, most patients with preexisting autoimmune …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

It is unanimously accepted that there is an unmet need for pain medications that are both
effective and safe. Unfortunately, no really novel analgesics have been approved over the …

Highlights•Co-medications must be carefully assessed at checkpoint inhibitors
initiation.•Withdrawal of proton pump inhibitors and psychotropic drugs should be …

Therapies targeting the programmed cell death 1 (PD-1) or its ligand (PD-L1) promote
antitumor T-cell activity, leading to unprecedented long-lasting tumor responses in some …

Introduction Immunotherapy may be an excellent choice for treating osteosarcoma given its
exceptionally high genomic instability, potentially generating neoantigens. In this study, we …